I also went back and re-read the phase II results after GRAS...

I also went back and re-read the phase II results after GRAS decision.

Re-reading the report, I also was reasonably impressed - the phase II was a tough test... effective dosage looks easily manageable within a food product.

One question I would have is how much it costs to produce and could be supplied at. This is probably more critical in a food application than in a pharmaceutical one. After that, it may be a matter of time to market, given the requirement for shelf-life testing.